Onyx Pharmaceuticals Inc. (ONXX): Today's Featured Drugs Winner

Onyx Pharmaceuticals (ONXX) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.2%. By the end of trading, Onyx Pharmaceuticals rose 51 cents (0.7%) to $72.53 on light volume. Throughout the day, 1.5 million shares of Onyx Pharmaceuticals exchanged hands as compared to its average daily volume of 2.2 million shares. The stock ranged in a price between $71.34-$72.94 after having opened the day at $71.91 as compared to the previous trading day's close of $72.02. Other companies within the Drugs industry that increased today were: Savient Pharmaceuticals (SVNT), up 24.1%, Rosetta Genomics (ROSG), up 9.4%, Targacept (TRGT), up 8.1%, and XenoPort (XNPT), up 8.1%.

• ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. Onyx Pharmaceuticals has a market cap of $4.65 billion and is part of the health care sector. The company has a P/E ratio of 249.2, above the average drugs industry P/E ratio of 240.9 and above the S&P 500 P/E ratio of 17.7. Shares are up 64.4% year to date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Onyx Pharmaceuticals a buy, no analysts rate it a sell, and two rate it a hold.

TheStreet Ratings rates Onyx Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share.

• You can view the full Onyx Ratings Report.

On the negative front, pSivida (PSDV), down 18.7%, Biosante Pharmaceuticals (BPAX), down 16%, Spectrum Pharmaceuticals (SPPI), down 14.3%, and Alimera (ALIM), down 14.1%, were all laggards within the drugs industry with Bristol-Myers Squibb Company (BMY) being today's drugs industry laggard.

• Use our drugs section to find industry-relevant news.
• Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF (XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech (BIS).

• Find other investment ideas from our top rated ETFs lists.

For more information on Onyx Pharmaceuticals Inc. click any of the following:

• Onyx Pharmaceuticals Inc. Stock Price

• Onyx Pharmaceuticals Inc. Analyst Ratings

• Onyx Pharmaceuticals Inc. Key Stats & Profile

• Onyx Pharmaceuticals Inc. Earnings

• Onyx Pharmaceuticals Inc. Ratio Comparison

• Onyx Pharmaceuticals Inc. Growth Rates

• Onyx Pharmaceuticals Inc. Balance Sheet

• Onyx Pharmaceuticals Inc. Cash Flow

• Onyx Pharmaceuticals Inc. Income Statement